STOCKHOLM, May 15, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that new pre-clinical data evaluating the potential of the lead candidate melflufen (melphalan ...

STOCKHOLM, Aug. 29, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the US Food and Drug Administration, FDA, has granted priority review for Oncopeptides' ...

Oncopeptides is developing melflufen, a first-in-class peptide-conjugated alkylator for the treatment of relapsed and refractory multiple myeloma. Oncopeptides, a pharmaceutical company based in ...

Please provide your email address to receive an email when new articles are posted on . Approximately one-quarter of patients with triple-class refractory multiple myeloma responded to treatment with ...

PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II ...

Dublin, March 02, 2023 (GLOBE NEWSWIRE) -- The "Melflufen Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. The report provides ...

Patients with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy experienced a durable clinical benefit after receiving melflufen (Oncopeptides) in ...

STOCKHOLM, June 3, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers ...

Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial Patients with RRMM refractory to pomalidomide ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted priority review to melflufen in combination with dexamethasone for the treatment of adults with ...

STOCKHOLM, May 15, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that new pre-clinical data evaluating the potential of the lead candidate melflufen (melphalan ...